216 related articles for article (PubMed ID: 18471998)
1. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus.
Chang YH; Lin IL; Tsay GJ; Yang SC; Yang TP; Ho KT; Hsu TC; Shiau MY
Clin Biochem; 2008 Aug; 41(12):955-9. PubMed ID: 18471998
[TBL] [Abstract][Full Text] [Related]
2. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus.
Shiau MY; Tsai ST; Tsai KJ; Haung ML; Hsu YT; Chang YH
Mt Sinai J Med; 2006 Nov; 73(7):1024-8. PubMed ID: 17195891
[TBL] [Abstract][Full Text] [Related]
3. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement.
Trysberg E; Blennow K; Zachrisson O; Tarkowski A
Arthritis Res Ther; 2004; 6(6):R551-6. PubMed ID: 15535833
[TBL] [Abstract][Full Text] [Related]
4. Elevated plasma stromelysin levels in arthritis.
Zucker S; Lysik RM; Zarrabi MH; Greenwald RA; Gruber B; Tickle SP; Baker TS; Docherty AJ
J Rheumatol; 1994 Dec; 21(12):2329-33. PubMed ID: 7699637
[TBL] [Abstract][Full Text] [Related]
5. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities.
Ainiala H; Hietaharju A; Dastidar P; Loukkola J; Lehtimäki T; Peltola J; Korpela M; Heinonen T; Nikkari ST
Arthritis Rheum; 2004 Mar; 50(3):858-65. PubMed ID: 15022328
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases in blood from patients with LAM.
Odajima N; Betsuyaku T; Nasuhara Y; Inoue H; Seyama K; Nishimura M
Respir Med; 2009 Jan; 103(1):124-9. PubMed ID: 18760908
[TBL] [Abstract][Full Text] [Related]
7. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.
Chang HR; Yang SF; Li ML; Lin CC; Hsieh YS; Lian JD
Clin Chim Acta; 2006 Apr; 366(1-2):243-8. PubMed ID: 16313894
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: correlation with systemic inflammatory markers and oxidative stress.
Bahrehmand F; Vaisi-Raygani A; Kiani A; Rahimi Z; Tavilani H; Ardalan M; Vaisi-Raygani H; Shakiba E; Pourmotabbed T
Lupus; 2015 May; 24(6):597-605. PubMed ID: 25416694
[TBL] [Abstract][Full Text] [Related]
9. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus.
Lesiak A; Narbutt J; Sysa-Jedrzejowska A; Lukamowicz J; McCauliffe DP; Wózniacka A
Lupus; 2010 May; 19(6):683-8. PubMed ID: 20064914
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients.
Bahrehmand F; Vaisi-Raygani A; Kiani A; Rahimi Z; Tavilani H; Navabi SJ; Shakiba E; Hassanzadeh N; Pourmotabbed T
Lupus; 2012 May; 21(6):616-24. PubMed ID: 22323339
[TBL] [Abstract][Full Text] [Related]
11. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus.
Robak E; Wierzbowska A; Chmiela M; Kulczycka L; Sysa-Jedrejowska A; Robak T
Mediators Inflamm; 2006; 2006(1):17898. PubMed ID: 16864898
[TBL] [Abstract][Full Text] [Related]
12. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 promoter polymorphisms in Korean patients with systemic lupus erythematosus.
Lee YJ; Woo M; Nam JH; Baek J; Im CH; Lee EY; Lee EB; Park KS; Song YW
Hum Immunol; 2008 Jun; 69(6):374-9. PubMed ID: 18571010
[TBL] [Abstract][Full Text] [Related]
14. [Stromelysin-1 (MMP-3) level in the sera from patients with rheumatoid arthritis and other connective tissue diseases--clinical significances in early onset rheumatoid arthritis].
Shingu M; Obata K; Ezaki I; Tomari K; Fujikawa Y; Wada T; Nonaka S; Suenaga Y; Iwata K; Nobunaga M
Ryumachi; 1995 Feb; 35(1):15-24. PubMed ID: 7732485
[TBL] [Abstract][Full Text] [Related]
15. Serum matrix metalloproteinase-3 in systemic sclerosis.
Jinnin M; Ihn H; Asano Y; Yamane K; Yazawa N; Tamaki K
Arch Dermatol Res; 2004 Jun; 296(1):25-9. PubMed ID: 15095096
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease.
Lee SD; Chen LM; Kuo WW; Shu WT; Kuo WH; Huang EJ; Tsai CC; Li PC; Liu JY; Chen TH; Huang CY
Clin Chim Acta; 2006 May; 367(1-2):62-8. PubMed ID: 16406300
[TBL] [Abstract][Full Text] [Related]
17. Systemic expression of matrix metalloproteinase-9 in patients with cerebral arteriovenous malformations.
Starke RM; Komotar RJ; Hwang BY; Hahn DK; Otten ML; Hickman ZL; Garrett MC; Sisti MB; Lavine SD; Meyers PM; Solomon RA; Connolly ES
Neurosurgery; 2010 Feb; 66(2):343-8; discussion 348. PubMed ID: 20087134
[TBL] [Abstract][Full Text] [Related]
18. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration.
Chau KY; Sivaprasad S; Patel N; Donaldson TA; Luthert PJ; Chong NV
Eye (Lond); 2007 Dec; 21(12):1511-5. PubMed ID: 17304258
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
